Meeting
2019 ASCO Annual Meeting
The consensus Immunoscore adapted to biopsies in patients with locally advanced rectal cancer: Potential clinical significance for a “Watch and Wait” strategy.
Authors
Carine El Sissy
Hopital Européen Georges Pompidou, Paris, France
Carine El Sissy , Amos Kirilovsky , Marc Van Den Eynde , Alfredo Romero , Florence Marliot , Christine Lagorce , Frédéric Bibeau , Ilma Soledad Iseas , Enrique Luis Roca , Carlos Alberto Vaccaro , David Tougeron , Carlos Torres Carvalho , Nuno Figueiredo , Rodrigo O Perez , Angelita Habr Gama , Viorel Scripcariu , Jean-Pierre Gerard , Jerome Galon , Guy Zeitoun , Franck Pages
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Immunotherapy and Tumor Immunobiology
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Tissue-Based Biomarkers
Citation
J Clin Oncol 37, 2019 (suppl; abstr 2628)
DOI
10.1200/JCO.2019.37.15_suppl.2628
Abstract #
2628
Poster Bd #
272
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Total neoadjuvant therapy (TNT) for locally advanced rectal cancer (LARC): Real-world experience from a tertiary Asian cancer center.
First Author: Meng Wang
Poster
2018 Gastrointestinal Cancers Symposium
Microsatellite instability as a predictive marker for response to neoadjuvant chemoradiation in locally advanced rectal cancer.
First Author: Rebecca Maria Shulman
Poster
2017 Gastrointestinal Cancers Symposium
Phase I study of neoadjuvant 5-fluorouracil (5FU) chemoradiation (CRT) and trametinib in patients with locally advanced rectal cancers (LARC).
First Author: Christina Sing-Ying Wu
Poster
2015 Gastrointestinal Cancers Symposium
Neoadjuvant chemoradiation (CRT) with or without panitumumab (Pan) in patients with K-ras unmutated, locally advanced rectal cancer (LARC): Final results of a randomized multicenter phase II trial (SAKK 41/07).
First Author: Daniel Helbling